Supplements

Medicinal cannabis improves quality of life and symptom control in advanced cancer patients

This Phase I/II double-blind, randomized controlled trial evaluates the safety, tolerability, and impact of medicinal cannabis on quality of life and symptom control in advanced cancer patients. The Phase II component specifically measures outcomes including pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden using validated instruments.

Last updated: Jul 25, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score42/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Phase I/II Double-Blind, Randomized Controlled Trial of Medicinal Cannabis on Quality of Life and Symptoms in Advanced Cancer: RESONANCE Trial Protocol.

observational

Wong AK, McMahon WR, Grobler A, Wilson C, Martin J, Galettis P, Mitchell P, Le B, Philip J, Gan H, Cebon J · Clinical therapeutics (2026)

Participants: N/A
Duration: N/A
Intervention: Medicinal cannabis (specific formulation not detailed in abstract)
Outcome: Quality of life, pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, caregiver burden
Effect Size: N/A
Population: People with advanced cancer

Result:

PubMed: 42476829DOI: 10.1016/j.clinthera.2026.06.018

Mechanism Graph

Medicinal cannabis interacts with endocannabinoid system
↓
Modulates neurotransmitter release
↓
Reduces inflammation and pain signaling
↓
Improves symptom burden and quality of life

Limitations

  • ⚠Abstract does not report final results or effect sizes
  • ⚠Phase I open-label design may introduce bias
  • ⚠Protocol adaptations for inclusivity may affect generalizability

Frequently Asked Questions

What is the purpose of the RESONANCE trial?▼

The trial aims to evaluate the safety, tolerability, and impact of medicinal cannabis on quality of life and symptom control in advanced cancer patients.

What symptoms are being measured in this study?▼

Symptoms measured include pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden.

Is this a randomized controlled trial?▼

Yes, the Phase II component is a double-blind, randomized clinical trial.

What is the significance of this research?▼

It aims to provide high-quality evidence to inform clinical practice and reduce decisional uncertainty for prescribers and patients regarding medicinal cannabis use in advanced cancer care.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Wong AK, McMahon WR, Grobler A, Wilson C, Martin J, Galettis P, Mitchell P, Le B, Philip J, Gan H, Cebon J. "Phase I/II Double-Blind, Randomized Controlled Trial of Medicinal Cannabis on Quality of Life and Symptoms in Advanced Cancer: RESONANCE Trial Protocol.." Clinical therapeutics, 2026. PMID: 42476829 DOI: 10.1016/j.clinthera.2026.06.018
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.